BergenstalRM, TamborlaneWV, AhmannA, et al.: Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med, 2010; 363:311–320.
2.
SloverRH, WelshJB, CriegoA, et al.: Effectiveness of sensor‐augmented pump therapy in children and adolescents with type 1 diabetes in the STAR 3 study. Pediatr Diabetes, 2012; 13:6–11.
3.
KropffJ, DeVriesJH: Continuous glucose monitoring, future products, and update on worldwide artificial pancreas projects. Diabetes Technol Ther, 2016; 18:S2–S53.
4.
ŠoupalJ, PetruželkováL, FlekačM, et al.: Comparison of different treatment modalities for type 1 diabetes, including sensor-augmented insulin regimens, in 52 weeks of follow-up: a COMISAIR study. Diabetes Technol Ther, 2016; 18:532–538.
5.
AndersonSM, RaghinaruD, PinskerJE, et al.: Multinational home use of closed-loop control is safe and effective. Diabetes Care, 2016:dc152468.
6.
BergenstalRM, GargS, WeinzimerSA, et al.: Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes. JAMA, 2016; 316:1407–1408.
7.
RenardE, FarretA, KropffJ, et al.: Day and night closed-loop glucose control in patients with type 1 diabetes under free-living conditions: results of a single-arm 1-month experience compared with a previously reported feasibility study of evening and night at home. Diabetes Care, 2016: dc160008.
8.
TauschmannM, AllenJM, WilinskaME, et al.: Home use of day-and-night hybrid closed-loop insulin delivery in suboptimally controlled adolescents with type 1 diabetes: a 3-week, free-living, randomized crossover trial. Diabetes Care, 2016; 39:2019–2025.
9.
SharifiA, De BockMI, JayawardeneD, et al.: Glycemia, treatment satisfaction, cognition, and sleep quality in adults and adolescents with type 1 diabetes when using a closed-loop system overnight versus sensor-augmented pump with low-glucose suspend function: a randomized crossover study. Diabetes Technol Ther, 2016; 18:772–783.
10.
BarnardKD, HoodKK, Weissberg-BenchellJ, et al.: Psychosocial assessment of artificial pancreas (AP): commentary and review of existing measures and their applicability in AP research. Diabetes Technol Ther, 2015; 17:295–300.
11.
BarnardKD, WysockiT, ThabitH, et al.: Psychosocial aspects of closed‐and open‐loop insulin delivery: closing the loop in adults with Type 1 diabetes in the home setting. Diabetic Med, 2015; 32:601–608.
12.
KropffJ, DeJongJ, FaveroS, et al.: Psychological outcomes of evening and night closed‐loop insulin delivery under free living conditions in people with Type 1 diabetes: a 2‐month randomized crossover trial. Diabetic Med, 2016; [Epub ahead of print], doi: 10.1111/dme.13268.
13.
Weissberg-BenchellJ, HesslerD, PolonskyWH, et al.: Psychosocial impact of the bionic pancreas during summer camp. J Diabetes Sci Technol, 2016; 10:840–844.
14.
YoungAJ, ThabitH, HellerSR, et al.: Holistic impact of closed-loop technology on people with type 1 diabetes. J Diabetes Sci Technol, 2015; 9:932–933.
15.
ZieglerC, LibermanA, NimriR, et al.: Reduced worries of hypoglycaemia, high satisfaction, and increased perceived ease of use after experiencing four nights of MD-Logic artificial pancreas at home (DREAM4). J Diabetes Res, 2015; 2015:doi:10.1155/2015/590308.
16.
MoskowitzDS, YoungSN: Ecological momentary assessment: what it is and why it is a method of the future in clinical psychopharmacology. J Psychiatry Neurosci, 2006; 31:13–20.
